Company: FENC
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001558370-25-005563
Chunk: 7

Company: FENNEC PHARMACEUTICALS INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 7
---
 at the Meeting has been fixed as 5:00 p.m. EDT on April 7, 2025 (the “Record Date”). Each Shareholder at the close of business (5:00 p.m. EDT) on the Record Date is entitled to attend the Meeting in person or by proxy and to cast one vote for each Common Share held by such Shareholder on the Record Date.

#### Quorum
According to the Corporation’s articles, the quorum for the transaction of business at any meeting of shareholders is two persons who are, or who represent by proxy, shareholders entitled to be voted at the meeting.

**Voting Securities and Principal Holders of Voting Securities**

As at April 7, 2025, there were 27,597,938 Common Shares issued and outstanding. Each Common Share carries the right to one vote at the Meeting.

Beneficial ownership of the Common Shares in the following table is determined in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Under these rules, a person is deemed to beneficially own a Common Share if that person has or shares voting power or investment power with respect to that share, or has the right to acquire beneficial ownership of that share within 60 days, including through the exercise of any option, warrant or other right or the conversion or any other security. Shares issuable under stock options and warrants are deemed

<div align='center'>Page4</div>

outstanding for computing the percentage of the person holding options or warrants but are not outstanding for computing the percentage of any other person. As at April 7, 2025, the directors and Named Executive Officers (defined below under “Executive Compensation–Summary Compensation Table”) of Fennec and, to the knowledge of the directors and Named Executive Officers of Fennec, after reasonable enquiry, their respective associates, as a group, beneficially owned, directly or indirectly, or exercised control or direction over 462,676 Common Shares (approximately 1.68% of all outstanding Common Shares on such date) and options and warrants to purchase 2,977,627 Common Shares (approximately 11.76% of the aggregate of all outstanding Common Shares on such date) exercisable within 60 days of April 7, 2025. The following table sets forth the number of Common Shares beneficially owned as of April 7, 2025 by: (1) each director and Named Executive Officer; (2) all directors and Named Executive Officers as